Biofrontera Inc (NASDAQ:BFRI) — Market Cap & Net Worth
Market Cap & Net Worth: Biofrontera Inc (BFRI)
Biofrontera Inc (NASDAQ:BFRI) has a market capitalization of $9.20 Million ($9.20 Million) as of May 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27086 globally and #5378 in its home market, demonstrating a 4.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biofrontera Inc's stock price $1.08 by its total outstanding shares 11648323 (11.65 Million). Analyse BFRI cash flow conversion to see how efficiently the company converts income to cash.
Biofrontera Inc Market Cap History: 2021 to 2026
Biofrontera Inc's market capitalization history from 2021 to 2026. Data shows change from $1.75 Billion to $12.58 Million (-62.35% CAGR).
Index Memberships
Biofrontera Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #789 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2561 of 3165 |
Weight: Biofrontera Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biofrontera Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biofrontera Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.34x
Biofrontera Inc's market cap is 0.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.75 Billion | $24.10 Million | -$37.71 Million | 72.69x | N/A |
| 2022 | $213.63 Million | $28.67 Million | -$640.00K | 7.45x | N/A |
| 2023 | $32.27 Million | $34.07 Million | -$20.13 Million | 0.95x | N/A |
| 2024 | $12.70 Million | $37.30 Million | -$17.76 Million | 0.34x | N/A |
Competitor Companies of BFRI by Market Capitalization
Companies near Biofrontera Inc in the global market cap rankings as of May 3, 2026.
Key companies related to Biofrontera Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Biofrontera Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Biofrontera Inc's market cap moved from $1.75 Billion to $ 12.58 Million, with a yearly change of -62.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $12.58 Million | +89.47% |
| 2025 | $6.64 Million | -47.71% |
| 2024 | $12.70 Million | -60.65% |
| 2023 | $32.27 Million | -84.90% |
| 2022 | $213.63 Million | -87.81% |
| 2021 | $1.75 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Biofrontera Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.20 Million USD |
| MoneyControl | $9.20 Million USD |
| MarketWatch | $9.20 Million USD |
| marketcap.company | $9.20 Million USD |
| Reuters | $9.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with t… Read more